<DOC>
	<DOCNO>NCT00721773</DOCNO>
	<brief_summary>This multicentre study examine effectiveness angiotension convert enzyme inhibitor ( ACEI ) , angiotensin receptor blocker ( ARB ) combination reduce rate decline residual renal function ( RRF ) continuous ambulatory peritoneal dialysis ( CAPD ) patient .</brief_summary>
	<brief_title>Renal Protective Effects Renin Angiotensin System ( RAS ) Inhibitor Peritoneal Dialysis Patients</brief_title>
	<detailed_description>RRF show decline progressively time dialysis CAPD hemodialysis . Although RRF important determinant mortality morbidity peritoneal dialysis ( PD ) patient , study address therapeutic approach preserve RRF initiation dialysis therapy . Blockade renin-angiotensin system ACEI ARB well-established approach renoprotection pre-dialysis chronic kidney disease patient . Up , two trial show ACEI , ramipril , ARB , valsartan , effective preservation RRF CAPD patient . However important point evidence cite limitation . First , trial involve patient one university teach hospital . Second , transport characteristic , assess start study . Third , trial small detect potentially important difference health care use survival group . Therefore , whether ACEI ARB preserve RRF , improve clinical outcome decrease health care use cost test much long large study involve multiple site . In order confirm finding , investigator perform prospective , randomize , open-label multiple center study address long-term effect ACEI , ARB combination therapy RRF Patients CAPD .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>All patient receive CAPD 1 month Subjects either sex , 2075 year old Residual GFR 3mL/min per 1.73 m2 With hypertension No history take ACE inhibitor angiotensinreceptor blocker least 1 month Provision write informed consent subject guardian Underlying medical condition , congestive heart failure , therapy ACE inhibitor ARB Peritonitis volume overload within precede 1 month Myocardial infarction within precede 6 month Clinically significant valvular disease Malignant hypertension History hypertensive encephalopathy cerebrovascular accident within precede 6 month Any condition may preclude patient remain study , alcohol drug abuse , chronic liver disease , malignant disease , psychiatric disorder History allergy intolerance ACE inhibitor ARB Participation another clinic trial within 2 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Continuous Ambulatory Peritoneal Dialysis</keyword>
	<keyword>Angiotensin-converting Enzyme Inhibitor</keyword>
	<keyword>Angiotensin II Receptor Blocker</keyword>
	<keyword>Renin angiotensin system inhibitor</keyword>
	<keyword>Residual Renal Function</keyword>
</DOC>